E

EyePoint Pharmaceuticals

EYPT

9.14000
USD
-0.75
(-7.58%)
Market Closed
Volume
5,117
EPS
0
Div Yield
0
P/E
-6
Market Cap
575,320,758
Related Instruments
A
ADMP
0
(0%)
0.000000 USD
A
ALLO
-0.21500
(-7.29%)
2.73500 USD
A
ARWR
-1.160
(-4.06%)
27.410 USD
A
ATNX
-0.34000
(-19.65%)
1.43000 USD
B
BLUE
-0.06000
(-5.26%)
1.08000 USD
B
BTAI
-0.09000
(-8.04%)
1.03000 USD
G
GMAB
0.065
(0.23%)
28.360 USD
M
MRSN
-0.20500
(-10.22%)
1.80000 USD
News

Title: EyePoint Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.